Previous close | 7.0300 |
Open | 1.6600 |
Bid | 0.2500 |
Ask | 5.8000 |
Strike | 505.00 |
Expiry date | 2024-07-26 |
Day's range | 0.0500 - 1.7500 |
Contract range | N/A |
Volume | |
Open interest | 2 |
BOSTON, July 01, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2024 financial results on Thursday, August 1, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Second Quarter 2024 Earnings Call."
The transaction was executed at a price of $471.72 per share, as detailed in the SEC Filing. Following this sale, the insider now owns 30,099 shares of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is a biotechnology firm focused on developing and commercializing therapies for the treatment of cystic fibrosis and other severe diseases.
While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.